WP
MDGL icon

Woodline Partners’s Madrigal Pharmaceuticals MDGL Stock Holding History

Woodline Partners’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$67.6M Hold
125,899
– – 0.21% 121
2026
Q1 		$65.9M Buy
125,899
+240
+0.2% +$115K 0.25% 94
2025
Q4 		$73.2M Buy
125,659
+21,812
+21% +$11.1M 0.28% 78
2025
Q3 		$47.6M Sell
103,847
-55,776
-35% -$20.8M 0.22% 121
2025
Q2 		$48.3M Sell
159,623
-157,810
-50% -$47M 0.26% 102
2025
Q1 		$105M Buy
317,433
+8,316
+3% +$2.73M 0.68% 15
2024
Q4 		$95.4M Buy
309,117
+162,027
+110% +$45.6M 0.64% 16
2024
Q3 		$31.2M Buy
147,090
+8,781
+6% +$2.25M 0.26% 124
2024
Q2 		$38.7M Buy
138,309
+118,609
+602% +$28.2M 0.37% 74
2024
Q1 		$5.26M Buy
+19,700
New +$4.64M 0.05% 352
2023
Q2 		– Sell
-12,358
Closed -$2.99M – 707
2023
Q1 		$2.99M Buy
12,358
+10,779
+683% +$2.94M 0.04% 372
2022
Q4 		$458K Sell
1,579
-16,544
-91% -$1.62M 0.01% 607
2022
Q3 		$1.18M Sell
18,123
-64,053
-78% -$4.45M 0.02% 524
2022
Q2 		$5.88M Buy
+82,176
New +$6.04M 0.09% 238

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Woodline Partners's MDGL Position: Q2 2026 in Review

Woodline Partners held its Madrigal Pharmaceuticals (MDGL) position steady in Q2 2026 at 125,899 shares worth $67.6M. The position accounts for 0.21% of the portfolio, ranked #121.

Woodline Partners first reported a position in MDGL in Q2 2022 and has held it in 14 quarters since. The position peaked at $105M in Q1 2025. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Woodline Partners held 125,899 shares of Madrigal Pharmaceuticals worth $67.6M as of Q2 2026.
  • Woodline Partners left its Madrigal Pharmaceuticals share count unchanged in Q2 2026.
  • Madrigal Pharmaceuticals made up 0.21% of Woodline Partners's portfolio in Q2 2026, its #121 holding.
  • Woodline Partners first reported a position in Madrigal Pharmaceuticals in Q2 2022 and has held it in 14 quarters since.
  • Woodline Partners's Madrigal Pharmaceuticals position peaked at $105M in Q1 2025.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.